Field Safety Corrective Actions and Recalls in Thailand

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

Field safety corrective actions, or FSCAs, are the recall-side counterpart of Thailand’s vigilance system, and their reporting windows are the shortest in the entire framework. This page explains what counts as an FSCA, when a report is triggered, what the initial and final reports must contain, how recalls are classified, and the independent enforcement powers held by the Secretary-General of the Thai FDA.

1. Key takeaways

An FSCA is an action taken in respect of a device already supplied, intended to reduce the risk of death or serious injury. It includes recalls, device modification, device replacement, device destruction, field safety notices, and updates and changes. A report is triggered when the product owner carries out any of these actions, whether in Thailand or abroad. The reporting rhythm is an initial report within 48 hours, followed by follow-up reports every 21 days until completion.

  • Initial report. Due within 48 hours from the date the reporter becomes aware that the action will be implemented. The trigger point is awareness that the action will be carried out, not the date the action is actually completed, so the 48-hour clock starts at the moment the recall decision is made.
  • Follow-up and final reports. Due every 21 days thereafter until the action is complete. The final report records the completion date, the effectiveness of the action and the disposal of affected stock.
  • Initial report content. Minimum content includes a description of the device defect or adverse event, the locations where the FSCA is implemented, the affected persons where an adverse event is involved, and a health hazard assessment with related documents. Under HPVC guidance, the initial report uses form Ror Mor Por 3, attaching the action strategy, the health hazard assessment if completed, and the field safety notice.
  • Recall classification. Three classes by potential health impact, with corresponding duties on recipients.
  • Thai FDA powers. Section 55 paragraph 5 of the Medical Device Act gives the Secretary-General independent powers of seizure and mandatory recall.

2. Legal basis

The FSCA reporting obligations derive from the FSCA provisions of the MoPH Notification B.E. 2563 (2020), which set the 48-hour initial report and the 21-day follow-up cycle. The definition of an FSCA in that notification covers recall, device modification, device replacement, device destruction, field safety notice, and updates and changes. Procedural requirements for the initial report, including form Ror Mor Por 3 and the three-class recall classification, come from HPVC guidance. Enforcement powers rest on Section 55 paragraph 5 of the Medical Device Act B.E. 2551 (2008), replaced in the 2019 amendment, which empowers the Secretary-General to act independently.

Recall classPotential health impactRecipient duty
Class 1Use is quite likely to cause serious permanent or long-term harm or deathImmediately quarantine affected stock and acknowledge receipt at once
Class 2Use may cause temporary or reversible effectsImmediately quarantine affected stock and acknowledge receipt at once
Class 3Adverse health effects are unlikely to occurAct by the date specified in the notice

Under Section 55 paragraph 5, for devices that do not conform to their authorisation or are unsafe, the Secretary-General may seize them from the manufacturer, importer, seller or holder, or order those parties to recall them from the market within a prescribed period, with the costs borne by those parties. Where the efficacy, quality or standards of a device do not match the registered dossier, or where the device is unsafe, the Secretary-General may execute a mandatory recall, publish the analysis results and contact the importer, manufacturer or distributor to implement it.

3. Expert insights

The single most consequential detail in the Thai FSCA regime is the starting point of the clock. The initial report is due within 48 hours from the date the reporter becomes aware that the action will be implemented, not from completion. This means the countdown begins at the moment the recall decision is made, which compresses the entire reporting preparation into a window shorter than two working days. Any capability that does not already exist at that moment, including translation capacity, hazard assessment templates and contact procedures, effectively cannot be built inside the window.

The second structural point is the dual-track nature of the regime. Companies run their own voluntary or company-initiated FSCAs under the notification and HPVC guidance, while the Secretary-General holds independent statutory powers to seize non-conforming or unsafe devices and order recalls at the obligation holders’ expense. A deficiency in the company-initiated track invites the statutory track, where the company loses control over timing, scope and messaging. Treating the 48-hour capability as a permanent readiness requirement, rather than an ad hoc response, is therefore not over-engineering but the minimum viable posture.

4. Practical recommendations

  • Recognise that the 48-hour window is extremely short, which means reporting capability must exist before the first report ever arrives. Prepare three things in advance.
  • First, a Thai-language template of the Ror Mor Por 3 form, so the primary submission can be completed in Thai without emergency translation.
  • Second, a health hazard assessment template, so the assessment accompanying the initial report can be assembled quickly from existing risk management documentation.
  • Third, a 24-hour contact mechanism with the licence holder, including holidays, so awareness transfers between parties without delay and the 48-hour clock can be managed from the moment the recall decision is made.
  • Build the follow-up cadence into the same procedure, scheduling reports every 21 days until completion and planning the final report contents, covering the completion date, the effectiveness of the action and the disposal of affected stock, from the outset rather than reconstructing them at the end.
  • Map the three recall classes onto internal triage criteria, including the immediate quarantine and acknowledgement duties for Class 1 and Class 2 recipients and the date-bound duty for Class 3, so downstream partners know their obligations before a notice is ever issued.

5. Verification checklist

  • □ Confirm the FSCA provisions of the MoPH Notification B.E. 2563 (2020): 48-hour initial report and 21-day follow-up cycle.
  • □ Confirm the FSCA definition: recall, device modification, device replacement, device destruction, field safety notice, and updates and changes.
  • □ Confirm the starting point is the date of awareness that the action will be implemented.
  • □ Confirm the minimum initial report content: description of the defect or adverse event, implementation locations, affected persons, and health hazard assessment.
  • □ Confirm HPVC guidance on form Ror Mor Por 3 and the three-class recall classification.
  • □ Confirm Section 55 paragraph 5 of the Medical Device Act B.E. 2551: the Secretary-General’s seizure and ordered recall powers, with costs borne by the obligation holders.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail